Package Leaflet: Information for the User
Detramax 2.5 mg/g + 15 mg/g Ointment
Hydrocortisone / Propanocaine Hydrochloride
Read this package leaflet carefully before you start using this medicine, because it contains important information for you.
Follow the instructions for administration of the medicine contained in this package leaflet or as indicated by your doctor or pharmacist .
Contents of the Package Leaflet
It contains as active ingredients for cutaneous use, hydrocortisone (a corticosteroid), with anti-inflammatory action and propanocaine hydrochloride, with local anesthetic effect.
Detramax is indicated for the temporary symptomatic relief of itching and skin pain due to minor skin irritations that respond to corticosteroids, such as contact allergy to soaps, detergents, metals, insect bites, jellyfish, and nettles.
Do not use Detramax:
Warnings and precautions
Consult your doctor or pharmacist before starting to use Detramax.
Children
Do not use in children under 12 years old unless prescribed by a doctor; in this case, it should be taken into account that diapers produce occlusion, which increases the absorption of the medicine.
Using Detramax with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medicine.
No interactions are known.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
As a general rule, during the first trimester of pregnancy, the ointment should not be applied.
It is recommended not to use this medicine during pregnancy unless your doctor considers it necessary, weighing the benefits against the potential risk.
Pregnant or breastfeeding women should not use Detramax on extensive skin areas or for a prolonged period, nor use occlusive dressings.
Do not apply Detramax to the breasts during breastfeeding.
Driving and using machines
Treatment with this medicine does not affect the ability to drive or use machines.
Detramax ointment contains cetyl alcohol, methyl parahydroxybenzoate (E-218), and propylene glycol
This medicine may cause local skin reactions (such as contact dermatitis) because it contains cetyl alcohol.
It may cause allergic reactions (possibly delayed) because it contains methyl parahydroxybenzoate (E218).
It may also cause skin irritation because it contains propylene glycol.
Follow the instructions for administration of the medicine contained in this package leaflet or as indicated by your doctor or pharmacist. In case of doubt, ask your doctor or pharmacist.
Topical use
Apply a small amount of ointment to the affected area 1 to 3 times a day with a gentle massage.
Wash your hands after each application.
If the symptoms persist for more than 5-7 days, according to the indication, or in case of worsening, you should interrupt treatment and consult your doctor.
Use in children
Do not use in children under 12 years old unless indicated by the doctor.
If you use more Detramax than you should
Using higher amounts of corticosteroids than recommended increases the risk of side effects.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately, go to your doctor, or call the Toxicology Information Service Phone: 91 562 04 20, indicating the medicine and the amount applied/taken.
If you forget to use Detramax
Do not use a double dose to make up for forgotten doses.
If you forget to apply the ointment at the scheduled time, apply it as soon as possible and continue with the usual routine.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The side effects that may occur are mainly due to excessive use of the medicine or use with occlusive dressing.
An allergic reaction such as contact dermatitis may occur.
The use of corticosteroids on the skin can lead to skin atrophy (thinning of the skin), telangiectasia (small veins visible on the skin), stretch marks, especially during prolonged treatments, redness, hirsutism (hair growth), bruising, acne, delayed healing, rosacea (inflammation with redness of the skin on the face), perioral dermatitis (inflammation around the mouth), secondary infection such as fungal, on skin or mucous membranes.
Prolonged use or on extensive areas may cause absorption through the skin and systemic effects (in areas of the body other than the application site), such as glaucoma (increased eye pressure), blurred vision - with an unknown frequency (cannot be estimated from available data) or may cause a disorder characterized by swelling of the face, neck, and obesity.
Reporting of side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this package leaflet. You can also report them directly through the Spanish Medicines and Health Products Agency (AEMPS) http://www.aemps.es/.
No special storage conditions are required.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the pharmacy's SIGRE point. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Detramax ointment
Appearance of the product and contents of the pack
Detramax is a white, shiny ointment with a smooth texture, presented in aluminum tubes.
Each tube contains 30 g.
Marketing authorization holder and manufacturer
Holder
Anotaciones Farmacéuticas S.L.
Cal1e D’Amposta, nº 14-18, planta 2 puerta 2B,
08174 - Sant Cugat del Vallés. Barcelona (Spain).
Manufacturer
Laboratorios Bohm, S.A.
C/ Molinaseca, 23. Polígono Industrial Cobo Calleja, Fuenlabrada,
28947 Madrid (Spain).
Date of the last revision of this package leaflet: April 2022
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.es/